Several different GLP-1 medications are approved specifically for weight loss, including Wegovy, Saxenda, and Zepbound
Because new Phase 3 obesity results announced in May 2026 drew major attention to its weight-loss potential
A patient in a medically supervised program can receive guidance on protein targets, exercise strategy, dose tolerance, hydration, digestion, lab markers, and adjunctive therapies when appropriate
Amy Rothberg, clinical professor of internal medicine in the Division of Metabolism, Endocrinology and Diabetes at the University of Michigan, says it also helps improve outcomes in people with type 2 diabetes and cardiorenal (heart and kidney) conditions, similar to semaglutide
By the second week, GLP-1 receptor activation begins to produce noticeable changes in gastric emptying
IFN: interferon